Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple supplement boost brain function in menopause?

NCT ID NCT06924541

Knowledge-focused Sponsor: Julie Dumas Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether low doses of choline, a nutrient found in foods like eggs, can change brain activity in postmenopausal women. Twenty healthy women aged 50–65 received either 550 mg, 1100 mg of choline, or a placebo on separate days. Researchers used brain scans (fMRI) to see if these doses affected brain signals during a memory task.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Choline (dietary supplement)
What this could lead to
If successful, this could show that lower choline doses affect brain function, pointing toward dietary strategies for cognitive health in menopause.
What could go wrong
This is a very small, early-stage study (20 people) looking at brain scans, not clinical outcomes. Results may not translate to real-world benefits or apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Sep 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 65 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged 50-65 years * Postmenopausal: Women who are postmenopausal will have not had a period in the last 12 months, have FSH\>30 IU/L, and estradiol (E2) \<50 pg/ml. * Nonsmokers * Not taking hormone therapy, SSRIs, phytoestrogens, SERMS, or antiestrogen medications and will be at least one year without such treatment * Physically healthy * No cardiovascular disease other than mild hypertension. Subjects will also not have current untreated or unremitted Axis I or II psychiatric or cognitive disorders (see screening below). * IQ in the normal range \>80 * Normal neuropsychological test performance Exclusion Criteria: * MCI or dementia - Montreal Cognitive Assessment \<26, Mattis Dementia Rating Scale \<130, and Global Deterioration Scale \>2 * History of cancer treatment with cytotoxic and/or ongoing (current) maintenance targeted chemotherapy * Blood pressure \> 160/100 (untreated) * Untreated thyroid disease * Significant cardiovascular disease * Asthma or COPD * Active peptic ulcer * Hyperthyroidism * Epilepsy * Current untreated or unremitted Axis I psychiatric disorders Use of medications on the Prohibited medications (see list)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Menopause are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Menopause

Contacts and locations

Locations

  • University of Vermont

    Burlington, Vermont, 05405, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.